BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun 2018;9:1219. [PMID: 29572535 DOI: 10.1038/s41467-018-03631-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Huang Y, Sun M, Wan S, Yang C, Song Y. Recent Advances in Aptamer-Based Liquid Biopsy. ACS Appl Bio Mater 2022. [PMID: 35014838 DOI: 10.1021/acsabm.1c01202] [Reference Citation Analysis]
2 Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Zabernigg AF, Egle D, Sandholzer M, Singer CF, Roitner F, Hager C, Andel J, Hubalek M, Knauer M, Greil R. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res 2021;23:112. [PMID: 34906198 DOI: 10.1186/s13058-021-01492-x] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
3 Raber HF, Kubiczek DH, Bodenberger N, Kissmann AK, D'souza D, Xing H, Mayer D, Xu P, Knippschild U, Spellerberg B, Weil T, Rosenau F. FluCell-SELEX Aptamers as Specific Binding Molecules for Diagnostics of the Health Relevant Gut Bacterium Akkermansia muciniphila. Int J Mol Sci 2021;22:10425. [PMID: 34638764 DOI: 10.3390/ijms221910425] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Ott M, Prins RM, Heimberger AB. The immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol 2021. [PMID: 34117475 DOI: 10.1038/s41571-021-00518-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kubiczek D, Raber H, Bodenberger N, Oswald T, Sahan M, Mayer D, Wiese S, Stenger S, Weil T, Rosenau F. The Diversity of a Polyclonal FluCell-SELEX Library Outperforms Individual Aptamers as Emerging Diagnostic Tools for the Identification of Carbapenem Resistant Pseudomonas aeruginosa. Chemistry 2020;26:14536-45. [PMID: 32515842 DOI: 10.1002/chem.202000213] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
6 Zon G. Recent advances in aptamer applications for analytical biochemistry. Anal Biochem 2020;:113894. [PMID: 32763306 DOI: 10.1016/j.ab.2020.113894] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hornung T, O'Neill HA, Logie SC, Fowler KM, Duncan JE, Rosenow M, Bondre AS, Tinder T, Maher V, Zarkovic J, Zhong Z, Richards MN, Wei X, Miglarese MR, Mayer G, Famulok M, Spetzler D. ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes. Nucleic Acids Res 2020;48:4013-27. [PMID: 31989173 DOI: 10.1093/nar/gkaa034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Haßel SK, Mayer G. Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided? Mol Diagn Ther 2019;23:301-9. [PMID: 31037641 DOI: 10.1007/s40291-019-00400-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
9 Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-ribeiro AB, Xavier CP, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019;46:100645. [DOI: 10.1016/j.drup.2019.100645] [Cited by in Crossref: 81] [Cited by in F6Publishing: 159] [Article Influence: 27.0] [Reference Citation Analysis]
10 El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin 2019;69:305-43. [PMID: 31116423 DOI: 10.3322/caac.21560] [Cited by in Crossref: 47] [Cited by in F6Publishing: 83] [Article Influence: 15.7] [Reference Citation Analysis]
11 Jani MS, Veetil AT, Krishnan Y. Precision immunomodulation with synthetic nucleic acid technologies. Nat Rev Mater 2019;4:451-8. [DOI: 10.1038/s41578-019-0105-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
12 Civit L, Theodorou I, Frey F, Weber H, Lingnau A, Gröber C, Blank M, Dambrune C, Stunden J, Beyer M, Schultze J, Latz E, Ducongé F, Kubbutat MHG, Mayer G. Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model. Sci Rep 2019;9:4976. [PMID: 30899039 DOI: 10.1038/s41598-019-41460-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Rinnerthaler G, Gampenrieder SP, Greil R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int J Mol Sci 2019;20:E1115. [PMID: 30841523 DOI: 10.3390/ijms20051115] [Cited by in Crossref: 51] [Cited by in F6Publishing: 78] [Article Influence: 17.0] [Reference Citation Analysis]
14 Yu TTL, Gupta P, Ronfard V, Vertès AA, Bayon Y. Recent Progress in European Advanced Therapy Medicinal Products and Beyond. Front Bioeng Biotechnol 2018;6:130. [PMID: 30298129 DOI: 10.3389/fbioe.2018.00130] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]